Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , may offer a notable advancement for obesity loss . Initial clinical tests have demonstrated impressive losses in abdominal tissue, potentially outperforming existing obesity medications . However , further assessment is required to thoroughly understand its long-